PEHA: PT Phapros Tbk - Summary | Jitta

PT Phapros Tbk

IDN:PEHA

Price
Rp298.00
Loss Chance
46.1%
3.47JITTA SCORE
45.12%Under Jitta Line
Jitta Ranking
93 / 855
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (51)
Recent Business Performance (76)
Financial Strength (56)
Return to Shareholders (22)
Competitive Advantage (46)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2024
Operating MarginInconsistent
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.47
45.12%
4.68
45.84%
4.29
428.89%
Pharmaceuticals
4.57
50.64%
3.68
133.17%
6.76
9.02%
COMPANY DESCRIPTION
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, X-Gra, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides ethical generic and branded products; and medical devices, as well as toll manufacturing. It also exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.